Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 25Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Neoplasms 12Colonic Neoplasms 9Uterine Cervical Neoplasms 7Lung Neoplasms 6Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma, Renal Cell 5Uterine Cervical Dysplasia 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Esophageal Neoplasms 4Brain Neoplasms 4Thrombocythemia, Essential 3Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Papillomavirus Infections 3Oropharyngeal Neoplasms 3Neuroblastoma 3Mouth Neoplasms 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Glioma 3Gallbladder Neoplasms 3Carcinoma, Hepatocellular 3

Interventions

Drug Therapy 2tremelimumab 1pembrolizumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Watchful Waiting 1Radiotherapy 1Palliative Care 1Magnetic Resonance Spectroscopy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle-invasive Bladder Cancer × Watchful Waiting × Clear all
NCT06686381 2025-02-05

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

American University of Beirut Medical Center

Phase 2 Not yet recruiting
80 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡